Drug Profile
Research programme: sulforafan analogues - Evgen Pharma/CSIC/University of Seville
Alternative Names: sulforafan analogues - Evgen Pharma/CSIC/University of SevilleLatest Information Update: 26 Apr 2023
Price :
$50
*
At a glance
- Originator CSIC; Evgen Pharma; Universidad de Sevilla
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Inflammation
Most Recent Events
- 27 Mar 2023 Sulforafan analogues licensed to Evgen Pharma worldwide (Evgen Pharma pipeline, March 2023)
- 27 Mar 2023 Sulforafan analogues is still in preclinical studies for Inflammation in Spain (Evgen Pharma pippeline, March 2023)
- 27 Mar 2023 Sulforafan analogues is still in preclinical studies for Inflammation in the UK (Evgen Pharma pippeline, March 2023)